Compare SCD & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCD | LCTX |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.0M | 366.2M |
| IPO Year | N/A | 1996 |
| Metric | SCD | LCTX |
|---|---|---|
| Price | $15.70 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 52.2K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 9.63% | N/A |
| EPS Growth | N/A | ★ 25.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,499,000.00 |
| Revenue This Year | N/A | $6.32 |
| Revenue Next Year | N/A | $124.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.19 |
| 52 Week Low | $13.35 | $0.37 |
| 52 Week High | $17.17 | $2.09 |
| Indicator | SCD | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 55.89 |
| Support Level | $15.44 | $1.55 |
| Resistance Level | $15.92 | $1.84 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 25.71 | 60.71 |
Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.